Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese

Chien, Kuo–Liong; Su, Ta‐Chen; Hsu, Hsiu-Ching; Chang, Wei‐Tien; Chen, Pei-Chung; Chen, Ming-Fong; Lee, Yuan‐Teh

doi:10.1016/j.ijcard.2008.10.045

Cited by 122 publications

(93 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 AF is associated with significant morbidity and mortality, and it is a major risk factor for thromboembolic events and death from all causes. 2 Numerous scoring systems have been proposed to predict thromboembolism risk in AF patients. Among these, the CHA 2 DS 2 -VASc score is currently the recommended clinical risk-prediction tool to evaluate the thromboembolism risk in patients with nonvalvular atrial fibrillation (NVAF).…”

Section: Introductionmentioning

confidence: 99%

Use of neutrophil‐lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study

Coşansu

Vatan

Gündüz

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

BackgroundAtrial fibrillation is one of the most common abnormal heart rhythms. Neutrophil‐lymphocyte ratio (NLR) has emerged as a potential marker for the level of inflammation in cardiac disorders.HypothesisNLR might be associated with thrombosis and bleeding risk scores and might predict cardioembolic risk in nonvalvular atrial fibrillation (NVAF) patients within the therapeutic international normalized ratio (INR).MethodsWe enrolled 272 patients taking warfarin for NVAF and classified them into 2 groups: Group A consisted of patients (n = 132) whose time in therapeutic range (TTR) was ≥65%, and Group B comprised patients (n = 139) whose TTR was <65%.ResultsNLR values were higher in group B than in group A (P < 0.0001). Patients classified as high risk according to CHA2DS2‐VASc score had significantly higher NLR levels (P = 0.002) than those classified as low and intermediate risk. Furthermore, NLR levels were significantly correlated with CHA2DS2‐VASc and HAS‐BLED scores (P < 0.001 and P < 0.0001, respectively). NLR predicted patients within therapeutic INR range (TTR ≥65%) with sensitivity of 81% and specificity of 71% in a receiver operator characteristic curve analysis, using a cutoff value of 2.17. Area under the curve for NLR was 0.81 (P < 0.0001).ConclusionsTo our knowledge, this is the first study showing correlation of NLR with both CHA2DS2‐VASc and HAS‐BLED risk scores. NLR might represent a useful marker to identify patients with high risks of stroke and bleeding and may have predictive value in identifying patients within the therapeutic INR range.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of neutrophil‐lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study

Coşansu

Vatan

Gündüz

et al. 2018

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…According to the research in Taiwan, the incidence of atrial fibrillation was 1.68 per 1000 people a year in male and 0.76 per 100 people a year in female. The overall prevalence of atrial fibrillation in Taiwanese is 1.4% in male and 0.7% in female [11]. The prevalence and incidence of atrial fibrillation increased substantially with age [11].…”

Section: Introductionmentioning

confidence: 99%

“…The overall prevalence of atrial fibrillation in Taiwanese is 1.4% in male and 0.7% in female [11]. The prevalence and incidence of atrial fibrillation increased substantially with age [11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Translation and Validation of the Taiwanese Version of the Self-Efficacy for Appropriate Medication Use Scale

Chen¹,

Wang²

2017

OJN

View full text Add to dashboard Cite

Aims and objectives: To translate and validate a Taiwanese version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS). Background: The major barrier in the management of atrial fibrillation is the lack of selfefficacy to medications adherence. Patients' knowledge of the nature of atrial fibrillation and cardiovascular, cerebrovascular risk factors and anticoagulants is a significant factor affecting individuals' adherence. However, few instruments have been developed to assess patients' self-efficacy to medications adherence and none has been translated into Taiwanese. Design: This study used a standard ''forward-backward'' procedure, which was used to translate SEAMS into Taiwanese language. Reliability was tested for internal consistency. Validity was confirmed using criterion-related validity. Methods: Data collection for this research occurred from October 13, 2015 to October 26, 2016. The sample included atrial fibrillation outpatient. Participants simultaneously completed the Taiwanese version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS-T). A total of 151 individuals completed the questionnaire. Results: Coefficient alpha was 0.931 for atrial fibrillation patients. Conclusions: Findings provide support for the validity of the Taiwanese version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS-T). Relevance to clinical practice: The translation and validation of an instrument evaluating the self-efficacy for medication adherence in atrial fibrillation contribute to assessing the provided educational intervention.

show abstract

“…8 The risk of AF-related stroke was higher in Caucasian populations than in Asians populations (see Figure 1). 4,[9][10][11][12][13][14][15] AF could in fact drive a prothrombotic or hypercoagulable state, by virtue of its fulfilment of Virchow's triad for thrombogenesis (blood stasis, endocardial dysfunction/damage, and abnormal haemostasis). The most important point in determining the strategy of stroke prevention for AF is how to estimate the thromboembolic (TE) risk accurately.…”

mentioning

confidence: 99%

Stroke in Atrial Fibrillation – Long-term Follow-up of Cardiovascular Events

Chao

Chiang

Chen

2013

Arrhythmia &Amp; Electrophysiology Review

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, accounting for approximately one-third of hospitalisations for cardiac rhythm disturbances.1 Between 1980 and 2000, the age-adjusted incidence of AF significantly increased from 3.04 to 3.68 per 1,000 person-years in the US. 2 The prevalence of AF was lower among African Americans than among Caucasians, 3 and it also seemed to be lower in the Asian population. 4,5 In a nationwide cohort of 702,502 participants in Taiwan, the AF incidence was around 1.5 per 1,000 person-years. 6 Since a considerable number of AF patients was paroxysmal in nature, the incidence and prevalence of AF could be significantly underestimated.Systemic thromboembolism is the most severe complication of AF. It accounts for about 15-20 % of ischaemic strokes.7 AF-related strokes were associated with a poor prognosis as more than 50 % of the survivors remain with a severe deficit, and recurrence may be as high as 12 % per year. 8 The risk of AF-related stroke was higher in Caucasian populations than in Asians populations (see Figure 1). 4,[9][10][11][12][13][14][15] AF could in fact drive a prothrombotic or hypercoagulable state, by virtue of its fulfilment of Virchow's triad for thrombogenesis (blood stasis, endocardial dysfunction/damage, and abnormal haemostasis). The most important point in determining the strategy of stroke prevention for AF is how to estimate the thromboembolic (TE) risk accurately. The CHADS 2 score is the most commonly used scheme in stroke risk stratifications for AF patients, 17 despite the fact that it classifies a large proportion of patients as being at 'intermediate risk', and several important TE risk factors were omitted in the scoring system. 18 Recently, a newly developed scoring system, CHA 2 DS 2 -VASc score, which extends the CHADS 2 scheme by considering additional stroke risk factors (vascular diseases and female gender) was recommended to be used to guide the antithrombotic therapies for AF patients. 19,20 The CHA 2 DS 2 -VASc score is most useful in identifying truly low-risk patients, and no antithrombotic therapy is necessary for patients with a CHA 2 DS 2 -VASc score of 0. [21][22][23] In the study performed by Taillandier et al., which enrolled a total of 616 AF patients with a CHA 2 DS 2 -VASc score of 0, an OAC was prescribed on an individual basis in 273 patients (44 %), antiplatelet therapy alone in 145 patients (24 %), and no antithrombotic therapy in 198 patients (32 %).22 During a follow-up of 876 ± 1,135 days, 38 patients experienced adverse events (10 stroke/thromboembolism, 19 major bleeding, 17 deaths). Prescription of OACs and/or antiplatelet therapy was not associated with an improved prognosis for stroke/thromboembolism (relative risk: 0.99, 95 % confidence interval: 0.25-3.99, p-value: 0.99), nor improved survival or net clinical benefit (combination of stroke/ thromboembolism, bleeding and death). More recently, a nationwide cohort study in Taiwan further demonstrated that AF males with a CHA 2 ...

show abstract

Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese

Cited by 122 publications

References 50 publications

Use of neutrophil‐lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study

Use of neutrophil‐lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study

Translation and Validation of the Taiwanese Version of the Self-Efficacy for Appropriate Medication Use Scale

Stroke in Atrial Fibrillation – Long-term Follow-up of Cardiovascular Events

Contact Info

Product

Resources

About